Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

Tandem Diabetes’ t:slim X2 Insulin Pump has received FDA approval for use alongside Dexcom’s G5 Mobile continuous glucose monitoring (CGM) technology. The approval is part of a rapid evolution ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...

Part of a broader initiative between the two companies to “develop and market products to help people better manage their diabetes”, Dexcom G5 Mobile users will now be able to sync their CGM ...

Dexcom also provided continuous glucose monitoring sensors at a discounted rate for this study. Note to editors: The author(s) declared the following potential conflicts of interest with respect ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

DexCom Call and Put Volume: 30-Day Overview Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional ...